Loading clinical trials...
Loading clinical trials...
The objective of the study aims to collect tumor tissue at the moment of progression under Immune checkpoint inhibitors (ICI) in biological resources center in Ambroise Paré hospital, in order to insure later study on molecular mechanism involving the progression of NSCLC and SCLC under ICI. The further analysis of research will be performed in the EA 4340 unity, Biomarkers and Clinical Trials in cancerology and onco-hematology, UVSQ, University of Paris-Saclay.
The study will consist of creation a tumor tissue bank, all sampling will be stored in the biological resources center of Ambroise Paré hospital.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Service de Pneumologie et Oncologie thoracique, Hôpital Ambroise Paré, APHP
Boulogne-Billancourt, France
Start Date
August 18, 2020
Primary Completion Date
August 1, 2027
Completion Date
August 1, 2027
Last Updated
September 3, 2025
50
ESTIMATED participants
Rebiopsy
PROCEDURE
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
NCT07485114
NCT07486219
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05692635